MIDRA Mandates Nano-Silver Migration Testing for Sterilization Packaging

On August 1, 2026, the Middle East Medical Device Regulators Alliance (MIDRA)—comprising Saudi Arabia, the UAE, and four other Gulf states—will enforce new biocompatibility requirements for sterilization packaging materials exported to the region. This update directly affects medical device packaging manufacturers, exporters, and distributors operating in or supplying to the Middle East market.

Event Overview

On May 2, 2026, MIDRA published the 2026 Material Biocompatibility Supplemental Guidance. Effective August 1, 2026, it mandates nano-silver migration testing (per ISO 10993-17:2025) for all sterilization packaging systems—including Tyvek, paper-plastic laminates, and similar materials—intended for sale in MIDRA member countries. The permissible limit is ≤0.5 μg/cm². Non-compliant products will not qualify for the MIDRA Joint Registration Certificate, a prerequisite for market access. This requirement has already been incorporated into distributor supplier qualification checklists across the region.

Industries Affected

Direct Exporters (China-based)

Chinese companies exporting sterilization packaging to MIDRA countries face immediate regulatory compliance pressure. Failure to complete nano-silver migration testing before August 1, 2026, blocks issuance of the MIDRA Joint Registration Certificate—effectively halting customs clearance and commercial distribution.

Material Suppliers & Converters

Suppliers of Tyvek, medical-grade papers, and plastic films used in final packaging assemblies must now provide migration test data—or enable their downstream converters to generate it. This introduces new technical documentation obligations and may trigger requalification of raw material batches if prior biocompatibility dossiers did not include nano-silver assessment.

Contract Manufacturers & Packagers

Third-party sterilization packaging assemblers serving Chinese OEMs must verify whether incoming substrates have been tested per ISO 10993-17:2025. If not, they bear responsibility for arranging and validating migration testing on finished package configurations—not just individual layers—since migration behavior depends on structure, sealing, and sterilization history.

Distributors & Regulatory Agents in MIDRA Countries

MIDRA-based distributors are updating supplier onboarding protocols to require certified nano-silver migration reports as part of technical file submissions. Absence of such documentation delays registration timelines and may result in automatic exclusion from tender eligibility lists for public healthcare procurement.

What Stakeholders Should Focus On Now

Confirm alignment with ISO 10993-17:2025 test methodology

ISO 10993-17:2025 specifies extraction conditions (e.g., solvent type, temperature, duration) and analytical detection limits. Companies should verify that their testing lab uses the exact parameters defined in the 2025 edition—not earlier versions—and issues reports explicitly referencing clause 6.3 (quantification of silver species).

Review existing product registrations and pending submissions

Registrations filed before May 2, 2026, are not grandfathered. MIDRA requires supplemental data submission for all active registrations—even those granted under prior guidance—if the product remains on the market after August 1, 2026. Prioritize high-volume SKUs and those supplied to national tenders.

Validate migration testing on final packaged configuration

Testing must be conducted on the complete, sealed package—including any adhesives, inks, or barrier coatings—not just substrate samples. Some labs previously tested raw materials only; affected firms must re-evaluate test scope and ensure full-package simulation reflects actual end-use conditions (e.g., ethylene oxide or gamma sterilization cycles).

Update technical documentation and internal SOPs

Quality management systems must reflect updated biocompatibility requirements. This includes revising design history files, risk management reports (ISO 14971), and supplier evaluation criteria to explicitly include nano-silver migration control as a critical parameter for sterilization packaging components.

Editorial Observation / Industry Insight

Observably, this is not merely a technical amendment but a signal of MIDRA’s broader convergence strategy toward harmonized, chemistry-informed biocompatibility oversight—mirroring recent EU MDR trends on elemental impurities and nanomaterials. Analysis shows the timing (May publication, August enforcement) suggests MIDRA prioritizes rapid implementation over extended transition periods, indicating limited tolerance for post-deadline exceptions. From an industry perspective, this shift elevates sterilization packaging from a passive functional component to an active biocompatibility-critical element—requiring deeper cross-functional engagement between materials science, regulatory affairs, and quality assurance teams. Current enforcement patterns suggest the requirement is already operational in practice, not merely prospective.

Conclusion: This regulation marks a definitive step toward stricter chemical safety accountability for medical packaging in the Middle East. It does not represent a temporary adjustment but a structural recalibration of regulatory expectations. Stakeholders should treat it as an established baseline—not a pending proposal—and align testing, documentation, and supply chain verification accordingly.

Source: MIDRA 2026 Material Biocompatibility Supplemental Guidance, published May 2, 2026. Note: Ongoing updates to MIDRA’s official portal and national implementation notices (e.g., SFDA Saudi Arabia, MOH UAE) remain under observation.